THE ERA OF COVID-19: WILL CONVALESCENT PLASMA AND INTRAVENOUS IMMUNOGLOBULINS BE THE ANSWER
AbstractSince the World Health Organization (WHO) declared severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) infection a pandemic in December 2019, observational and interventional studies have been underway to investigate potential therapeutic options to treat and prevent the progression of coronavirus disease (COVID-19). Most COVID-19 patients develop mild to moderate symptoms. However, elderly patients suffering from chronic comorbidities and immunocompromised patients are susceptible to more severe life-threatening presentations. Convalescent plasma and intravenous immunoglobulins (IVIg) are two attractive options for managing and preventing severe COVID-19. However, current literature does not confirm nor deny the efficacy of the convalescent plasma and IVIg against COVID-19. Moreover, there is much concern considering the safety of blood-derived immune products. For these reasons, the current clinical guidelines do not recommend for or against the use of blood-derived immune products for managing COVID-19 cases. This article summarizes recent evidence on the safety and efficacy of the convalescent plasma and IVIg in COVID-19 patients.
Article Information
14
1967-1971
483 KB
351
English
IJPSR
Dalia A. Aly, Rana M. Kelany, Nada M. Abd El-rahman, Rana Sayed * and Nagwa A. Sabri
Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
ranasayed@pharma.asu.edu.eg
29 July 2021
01 September 2021
14 September 2021
10.13040/IJPSR.0975-8232.13(5).1967-71
01 May 2022
Download